Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trialRobert L Coleman, Domenica Lorusso, Ana Oaknin, Sabrina Chiara Cecere, Hannelore Denys, Nicoletta Colombo, Toon van Gorp, Jason A Konner, Margarita Romeo Marin, Philipp Harter, Conleth Murphy, Yuemei Wang, Brooke Esteves, Michael Method, Ursula Matulonis
10 June 2024
Radical vaginal trachelectomy: long-term oncologic and fertility outcomes in patients with early cervical cancerChristhardt Kohler, Andrea Plaikner, Kathrin Siegler, Hermann Hertel, Kati Hasenbein, Anja Petzel, Melanie Schubert, Jens-Uwe Blohmer, Gerd Böhmer, Claudia Stolte, Simone Marnitz, Nina Mallmann-Gottschalk, Peter Oppelt, Giovanni Favero, Silke WestphalenSee the full list of authors
10 April 2024
Rectal sparing in modified posterior exenteration: description of the technique in 10 stepsNavid Mokarram Dorri, Guillaume Blache, Jonathan Garnier, Gilles Houvenaeghel, Houssein El Hajj, Eric Lambaudie
21 March 2024
Impact of electronic medical record utilization on obesity screening and intervention for obese patients with endometrial cancerKayla Atessa Buttafuoco, Shilpa Mokshagundam, Anna Henricks, Summer Shore, Alaina Brown, Lauren Shore Prescott
22 March 2024
Analysis of risk factors for post-operative recurrence or progression of intravenous leiomyomatosisGuorui Zhang, Xin Yu, Jinghe Lang, Bao Liu, Dachun Zhao
19 March 2024
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trialTine Ottenbourgs, Toon van Gorp, Frédéric Kridelka, Thaïs Baert, Hannelore Denys, Frédéric Selle, Inge Baas, Anne-Sophie Van Rompuy, Diether Lambrechts, Els Van Nieuwenhuysen
6 March 2024
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trialDomenica Lorusso, Marie-Ange Mouret-Reynier, Philipp Harter, Claire Cropet, Cristina Caballero, Pia Wolfrum-Ristau, Toyomi Satoh, Ignace Vergote, Gabriella Parma, Trine J Nøttrup, Coriolan Lebreton, Peter A Fasching, Carmela Pisano, Luis Manso, Hugues BourgeoisSee the full list of authors
21 December 2023
Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumorsKoji Matsumoto, Yoshinori Sunaga, Evelyne Ecstein-Fraisse, Keiichi Fujiwara
20 November 2023
Staging by imaging in gynecologic cancer and the role of ultrasound: an update of European joint consensus statementsDaniela Fischerova, Carolina Smet, Umberto Scovazzi, Diana Natacha Sousa, Kristina Hundarova, Ingfrid Salvesen Haldorsen
4 March 2024
Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapySergio Cedillo, Carla Garí, Susana Aceituno, Luis Manso, Ana Cristina Cercos Lleti, Pedro Ventayol Bosch, Antonio Casado, Alejandro Perez Fidalgo
2 December 2023